GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (NAS:ADVM) » Definitions » 3-Year EBITDA Growth Rate

ADVM (Adverum Biotechnologies) 3-Year EBITDA Growth Rate : 22.00% (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies 3-Year EBITDA Growth Rate?

Adverum Biotechnologies's EBITDA per Share for the three months ended in Mar. 2025 was $-2.27.

During the past 3 years, the average EBITDA Per Share Growth Rate was 22.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 6.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 5.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Adverum Biotechnologies was 22.00% per year. The lowest was -172.00% per year. And the median was 1.00% per year.

Competitive Comparison of Adverum Biotechnologies's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Adverum Biotechnologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adverum Biotechnologies's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's 3-Year EBITDA Growth Rate falls into.


;
;

Adverum Biotechnologies 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Adverum Biotechnologies  (NAS:ADVM) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Adverum Biotechnologies 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Adverum Biotechnologies Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (NAS:ADVM) » Definitions » 3-Year EBITDA Growth Rate
Comparable Companies
APLT VRCA PPCB KLRS DTIL RNXT ATRA HOWL TELO RENB VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
0HA3:UK AVU0:Germany
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Website
https://www.adverum.com
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Executives
Peter Soparkar officer: Chief Legal Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Setareh Seyedkazemi officer: Chief Development Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL DRIVE, REDWOOD CITY CA 94063
Laurent Fischer director, officer: CEO and Director C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Lupher, Jr. Mark L. director C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK CA 94025
James Paul Scopa director 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
C. David Nicholson, director 103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Linda M Rubinstein officer: Chief Financial Officer 25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Brigit Riley officer: Chief Scientific Officer 100 CARDINAL WAY, REDWOOD CITY CA 94063
Richard Beckman officer: Chief Medical Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Nancy E Pecota officer: Principal Accounting Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
John Rakow officer: SVP, Genl Counsel, Acting CFO C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Rupert D'souza officer: Chief Financial Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Soo Hong director C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063
Rabia Gurses Ozden director C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210